公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | $1.1B | $606M | $364M | $305M | $245M | $188M | $164M | $136M | $10M | $0M | $0M | $0M | $12M | $12M | $0M | $4M | $7M | $10M | $12M | $8M | $1M |
| 売上総利益 | $947M | $482M | $278M | $240M | $190M | $144M | $125M | $112M | $7M | ($3M) | ($2M) | ($2M) | ($22M) | ($18M) | ($21M) | $4M | $7M | $10M | $12M | $7M | $0M |
| 売上総利益率 % | 83.2% | 79.4% | 76.4% | 78.5% | 77.5% | 76.6% | 75.8% | 82.3% | 75.4% | — | — | — | -191.6% | -157.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | 92.3% | -50.3% |
| 営業利益（EBIT） | ($917M) | ($1.2B) | ($878M) | ($710M) | ($457M) | ($375M) | ($265M) | ($235M) | ($307M) | ($189M) | ($173M) | ($117M) | ($87M) | ($55M) | ($42M) | ($62M) | ($8M) | ($9M) | ($14M) | ($20M) | ($54M) |
| 営業利益率 % | -80.6% | -194.0% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3124.9% | — | — | — | -759.7% | -478.4% | — | -1397.3% | -116.9% | -83.6% | -123.2% | -271.5% | -5486.7% |
| 当期純利益 | ($875M) | ($1.3B) | ($914M) | ($750M) | ($482M) | ($435M) | ($294M) | ($254M) | ($324M) | ($193M) | ($176M) | ($118M) | ($79M) | ($56M) | ($41M) | ($60M) | ($6M) | $118M | ($16M) | ($20M) | ($56M) |
| 純利益率 % | -76.9% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — | — | -688.3% | -487.6% | — | -1350.8% | -93.0% | 1140.9% | -133.9% | -265.1% | -5664.9% |
| EBITDA | — | ($1.2B) | ($819M) | ($660M) | ($447M) | ($384M) | ($250M) | ($217M) | ($295M) | ($184M) | ($170M) | ($115M) | ($86M) | ($54M) | ($40M) | ($59M) | ($6M) | $120M | ($13M) | ($20M) | ($51M) |
| 1株当たり利益（EPS） | $-4.11 | $-5.98 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 | $-2.02 | $-1.84 | $-1.60 | $-1.56 | $-2.56 | $-0.49 | $9.30 | $-1.28 | $-1.74 | $-5.89 |
| 発行済株式数（百万株） | — | 214M | 164M | 140M | 123M | 112M | 98M | 85M | 77M | 67M | 62M | 59M | 43M | 35M | 27M | 23M | 13M | 13M | 12M | 11M | 10M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は INSM のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/INSM
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms